First experience of using casirivimab/imdevimab in COVID-19 in the Russian Federation

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2022-01-01 DOI:10.20953/1729-9225-2022-3-129-132

P. Bogomolov, A. O. Bueverov, E. Bueverova, A.A. Кhvan, I. Maev, M.V. Arapova, N.A. Shub, E. A. Isaeva, S. V. Koblov

{"title":"First experience of using casirivimab/imdevimab in COVID-19 in the Russian Federation","authors":"P. Bogomolov, A. O. Bueverov, E. Bueverova, A.A. Кhvan, I. Maev, M.V. Arapova, N.A. Shub, E. A. Isaeva, S. V. Koblov","doi":"10.20953/1729-9225-2022-3-129-132","DOIUrl":null,"url":null,"abstract":"The lack of effective etiotropic therapy is a serious challenge in the treatment of patients with COVID-19. The recent emergence of a new class of medications neutralizing monoclonal antibodies against the SARS-CoV-2 spike protein allows to partially solve this problem. This article presents a clinical case of a patient with an increased risk of COVID-19 complications (paroxysmal atrial fibrillation, atherogenic dyslipidemia, impaired carbohydrate tolerance) who was treated with 600 mg casirivimab and 600 mg imdevimab by intravenous infusion. A significant improvement in the patient's well-being was noted within the first 24 hours: normalization of body temperature, stool, reduction of weakness, disappearance of arthralgia and myalgia. After 48 hours, a negative test result for SARS-CoV-2 RNA was obtained, which altogether made it possible to state the recovery. There were no adverse events during and after therapy. The casirivimab and imdevimab monoclonal antibody combination may be considered as a promising etiotropic treatment for COVID-19. Key words: COVID-19, monoclonal antibodies, casirivimab, imdevimab, treatment","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2022-3-129-132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The lack of effective etiotropic therapy is a serious challenge in the treatment of patients with COVID-19. The recent emergence of a new class of medications neutralizing monoclonal antibodies against the SARS-CoV-2 spike protein allows to partially solve this problem. This article presents a clinical case of a patient with an increased risk of COVID-19 complications (paroxysmal atrial fibrillation, atherogenic dyslipidemia, impaired carbohydrate tolerance) who was treated with 600 mg casirivimab and 600 mg imdevimab by intravenous infusion. A significant improvement in the patient's well-being was noted within the first 24 hours: normalization of body temperature, stool, reduction of weakness, disappearance of arthralgia and myalgia. After 48 hours, a negative test result for SARS-CoV-2 RNA was obtained, which altogether made it possible to state the recovery. There were no adverse events during and after therapy. The casirivimab and imdevimab monoclonal antibody combination may be considered as a promising etiotropic treatment for COVID-19. Key words: COVID-19, monoclonal antibodies, casirivimab, imdevimab, treatment

查看原文本刊更多论文

俄罗斯联邦在COVID-19中首次使用卡西维单抗/依德维单抗的经验

缺乏有效的致病因治疗是COVID-19患者治疗中的一个严重挑战。最近出现的一类新的药物可以中和针对SARS-CoV-2刺突蛋白的单克隆抗体，这可以部分解决这个问题。本文报道了1例新冠肺炎并发症(阵发性心房颤动、动脉粥样硬化性血脂异常、碳水化合物耐受性受损)风险增加的患者，静脉输注600mg卡西维单抗和600mg伊德维单抗治疗。在最初的24小时内，患者的健康状况有了显著改善:体温、大便恢复正常，虚弱减轻，关节痛和肌痛消失。48小时后，获得了SARS-CoV-2 RNA的阴性检测结果，这使得恢复成为可能。治疗期间和治疗后均无不良事件发生。卡西维单抗与伊德维单抗联合治疗可能被认为是一种很有前途的促病因治疗方法。关键词:COVID-19，单克隆抗体，卡西维单抗，依德维单抗，治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.